Kobayashi Shinjiro, Suzuki Miho, Tsuneki Hiroshi, Nagai Ryoji, Horiuchi Seikoh, Hagino Nobuyoshi
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanagawa-Machi, Kanazawa, Japan.
Biol Pharm Bull. 2004 Oct;27(10):1565-71. doi: 10.1248/bpb.27.1565.
Action of N(epsilon)-(carboxymethyl)lysine (CML) adduct, an advanced glycation end product, was investigated on neovascularization of cultured choroidal explants in streptozotocin (STZ)-diabetic rat. The choroidal explants of early (4 weeks after an injection of 60 mg/kg STZ) and advanced (8 months after the STZ injection) diabetic rats, and age-matched normal rats were cultured in fibrin gel with Dulbecco's modified Eagle medium containing fetal bovine serum. The number of budded microvessel-like structures was counted and used as an index of in vitro neovascularization. Choroidal explants in the early diabetic stage released vascular endothelial growth factor (VEGF) and tended to increase tumor necrosis factor (TNF) alpha and platelet-derived growth factor (PDGF)-B, and concomitantly facilitated growth of sprout and buds, compared to the normal control. When choroidal explants were stimulated with CML-human serum albumin (HSA), its releasing effect was in the order VEGF>TNFalpha>PDGF-B. CML-HSA and CML-bovine serum albumin augmented the neovascularization in the cultured diabetic explant and their actions did not virtually differ. A monoclonal anti-CML antibody (6D12) inhibited the neovascularization in the advanced diabetes greater than that in the early diabetes. Inhibitory actions of anti-VEGF and anti-TNFalpha antibodies on the neovascularization were similar to that of the anti-CML antibody in the diabetes. In conclusion, CML adducts were accumulated and over-produced the actions of VEGF, TNFalpha and PDGF-B in the choroidal explant during diabetes in an age-dependent manner. TNFalpha and VEGF are likely to play a predominant role for the CML-induced choroidal neovascularization.
研究了晚期糖基化终产物N-ε-(羧甲基)赖氨酸(CML)加合物对链脲佐菌素(STZ)诱导的糖尿病大鼠脉络膜外植体新生血管形成的作用。将早期(注射60mg/kg STZ后4周)和晚期(STZ注射后8个月)糖尿病大鼠以及年龄匹配的正常大鼠的脉络膜外植体在含有胎牛血清的杜氏改良 Eagle 培养基的纤维蛋白凝胶中培养。对出芽的微血管样结构进行计数,并将其用作体外新生血管形成的指标。与正常对照组相比,糖尿病早期的脉络膜外植体释放血管内皮生长因子(VEGF),并倾向于增加肿瘤坏死因子(TNF)α和血小板衍生生长因子(PDGF)-B,同时促进芽和芽的生长。当用CML-人血清白蛋白(HSA)刺激脉络膜外植体时,其释放作用顺序为VEGF>TNFα>PDGF-B。CML-HSA和CML-牛血清白蛋白增强了培养的糖尿病外植体中的新生血管形成,它们的作用实际上没有差异。单克隆抗CML抗体(6D12)对晚期糖尿病新生血管形成的抑制作用大于早期糖尿病。抗VEGF和抗TNFα抗体对新生血管形成的抑制作用与糖尿病中抗CML抗体的作用相似。总之,在糖尿病期间,CML加合物在脉络膜外植体中积累并以年龄依赖的方式过度产生VEGF、TNFα和PDGF-B的作用。TNFα和VEGF可能在CML诱导的脉络膜新生血管形成中起主要作用。